Johnson & Johnson's Q2 Earnings: Revenue And Profit Beat On Strong Pharma Sales, Annual Profit Outlook Lowered On M&A CostsBenzinga • 07/17/24
Johnson & Johnson Earnings Top, But Dow Stock Falls On Lowered GuidanceInvestors Business Daily • 07/17/24
Johnson & Johnson stock gets a lift from earnings beat, while outlook was mixedMarket Watch • 07/17/24
Johnson & Johnson Earnings Are Coming. It Took Steps to Put Its Talc Issues Behind It.Barrons • 07/16/24
Unlocking Q2 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key MetricsZacks Investment Research • 07/12/24
Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26Business Wire • 07/11/24
3 Magnificent Dow Stocks That Are No-Brainer Buys for the Second Half of 2024The Motley Fool • 07/11/24